Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advisory Cmte. Conflict of Interest Waivers Common; Avandia Is High Water Mark

Executive Summary

As currently convened, the majority of FDA advisory committee meetings on drugs would likely violate a limit on participation by experts with a financial conflict of interest being considered by Congress

You may also be interested in...



FDA Casts Wide Net For Advice on Avandia

Agency increases number of voting members for the meeting of the Endocrinologic and Metabolic and Drug Safety and Risk Management Advisory Committees to 33, up 10 from 2007. Half of the committee's voting members also participated in the first review of rosiglitazone's postmarketing safety.

Advisory Committee Conflict Of Interest Waivers Get Support From Study

FDA's policy of granting waivers for financial conflicts of interest for advisory committee members is getting support from an independent review. According to an analysis commissioned by the agency, constructing advisory committees free from conflicts of interest would be expensive and time-consuming and may be unfeasible for certain topics and fields of expertise

Advisory Committee Conflict Of Interest Waivers Get Support From Study

FDA's policy of granting waivers for financial conflicts of interest for advisory committee members is getting support from an independent review. According to an analysis commissioned by the agency, constructing advisory committees free from conflicts of interest would be expensive and time-consuming and may be unfeasible for certain topics and fields of expertise

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel